Overview Rituximab and ABVD for Hodgkin's Patients Status: Completed Trial end date: 2012-03-01 Target enrollment: Participant gender: Summary Primary Objective: - To determine the feasibility, toxicity, and efficacy of Rituximab with standard dose ABVD combination chemotherapy. ABVD combination chemotherapy consists of Adriamycin, Bleomycin, Vinblastine and DTIC. Phase: Phase 2 Details Lead Sponsor: M.D. Anderson Cancer CenterCollaborator: Genentech, Inc.Treatments: BleomycinDacarbazineDoxorubicinLiposomal doxorubicinRituximabVinblastine